Clinical Trial Update: ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study by ImmunityBio is evaluating N-803 plus tislelizumab and docetaxel versus docetaxel alone in advanced or metastatic non-small cell lung cancer, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• N-803
• Tislelizumab (tislelizumab)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: NSCLC Stage IV | Phase 3 | Status: RECRUITING